

## Special Issue

# Clinical and Translational Updates in Renal Cell Carcinoma

### Message from the Guest Editor

This special issue aims to highlight the latest clinical and translational developments in renal cell carcinoma. We welcome original manuscripts (preferred) and high-quality reviews covering updates on both early and advanced renal cell carcinoma. We welcome manuscripts covering various aspects, including developments related to basic and translational science, molecular and computational biology, artificial intelligence, and machine learning, as well as the clinical management of nuanced issues in the perioperative/adjuvant and metastatic setting. If you have an interesting proposal related to renal cell carcinoma that is not covered by the categories listed above, please feel free to submit your proposal for consideration. We look forward to receiving your high-quality contributions.

---

### Guest Editor

Dr. Irbaz Bin Riaz

Mayo Clinic Arizona, Alix School of Medicine, Rochester, MN, USA

---

### Deadline for manuscript submissions

closed (15 December 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/137902](https://mdpi.com/si/137902)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)